BTIG downgraded Orchestra BioMed (OBIO) to Neutral from Buy without a price target The firm cites the company’s recent dilutive equity financing while maintaining its pace of spending for the downgrade. The funding reduces Orchestra’s future profitability while its key catalyst timelines have slipped over the past several quarters, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO:
- Orchestra BioMed Reports Q2 2025 Financial Results
- Orchestra BioMed announces publication of AVIM data in JACC
- Orchestra BioMed reports Q2 EPS (50c), consensus (51c)
- Orchestra BioMed announces rollout of FDA-approved BACKSEAT study update
- Orchestra BioMed secures over $111M in proceeds, committed capital